American Medical Association

By Monica Guzman, Seattle PI Staff

Marijuana has long been classified as a dangerous drug with no medical benefits. But thanks in part to the work of a University of Washington medical student, a major medical association this week urged the federal government to reconsider.

"It's a huge shift on medical ideology," said Sunil Aggarwal, who's been studying the medical uses of marijuana for 10 years. "It's something I've been dreaming of since I was an undergraduate and found out that marijuana wasn't a horribly dangerous thing."

Since 1997, the American Medical Association has taken a hard line against the drug, endorsing its classification as a Schedule 1 controlled substance -- the most restrictive category -- and asserting its lack of medical value. Aggarwal's research, published in his dissertation and in two articles in the Journal of Opioid Management -- helped convince AMA members that the drug has potential.

More Research Is Needed, But Difficult to Fund Due to Stigma, Experts Say

By Joseph Brownstein, GMA

Given the many challenges involved in raising an autistic child, parents are willing to try a variety of potential remedies, many of which are controversial and unproven.

But one potential treatment that has gained attention recently is one that was controversial well before its first mention in connection with autism.

"At first I did some research, and I found a doctor who actually had a protocol for medical marijuana in children diagnosed with autism," Mieko Hester-Perez of Fountain Valley, Calif., told "Good Morning America."

Hester-Perez made her decision to try giving her 10-year-old son, Joey Perez, medical marijuana after his weight had become dangerously low due to his unwillingness to eat. She said that at the time she began the approach, he weighed only 46 pounds.

"You could see the bones in his chest. He was going to die," she said.

By Stephanie Condon, CBS News

The American Medical Association on Tuesday adopted a resolution calling for the government to review its classification of marijuana, in order to ease the way for more research into the use of medical marijuana.

While the AMA, the largest physician's organization in the U.S., explicitly states it does not endorse any current state-based medical marijuana programs or the legalization of marijuana, the move is a significant shift that continues a trend toward support for easing restrictions against the drug.

"Our American Medical Association (AMA) urges that marijuana's status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines," the AMA's statement (PDF) reads. "This should not be viewed as an endorsement of state-based medical cannabis programs, the legalization of marijuana, or that scientific evidence on the therapeutic use of cannabis meets the current standards for a prescription drug product."

By Daniel Tencer

The American Medical Association on Tuesday issued a cautious but historically significant call to change America's marijuana prohibition laws, urging a "review" of the drug's status as a Schedule I drug.

At a meeting in Houston, the AMA's House of Delegates adopted a new policy that calls for "marijuana's status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines, and alternate delivery methods."

That does not mean the AMA supports the legalization or decriminalization of marijuana.

Schedule I drugs are those considered to have no medical benefit and to be harmful when used under any circumstances. As such, marijuana is currently grouped by the federal government with drugs like heroin and LSD. By comparison, cocaine and methamphetamines are classified as Schedule II drugs, which may have some clinical benefits when used in the proper circumstances. The AMA's stance could simply result in the rescheduling of marijuana as a controlled substance that has some medical benefit.

However, Aaron Houston, director of government relations for the Marijuana Policy Project, calls the move "historic" all the same, noting that it comes from "what has historically been America's most cautious and conservative major medical organization."
Story continues below...